Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 524470 | NSE Symbol : SYNCOMF | ISIN : INE312C01025 | Industry : Pharmaceuticals - Indian - Formulations |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
10-Feb-2025	10-Feb-2025	Quarterly Results	Consideration and approval of standalone and consolidated unaudited financial results for the quarter and nine months ended 31.12.2024
04-Nov-2024	11-Nov-2024	Quarterly Results	SYNCOM FORMULATIONS (INDIA) LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2024 inter alia to consider and approve Pursuant to Regulation 29(1) (a) of SEBI (LODR) Regulations 2015 read with SEBI (PIT) Regulations 2015 as amended from time to time we are pleased to inform that 3/2024-25 Meeting of the Board of Directors of the Company is scheduled to be held on Monday the 11th day of November 2024 at 4:00 P.M. at the Corporate Office situated at 207 Saket Nagar Near Saket Club Indore (M.P.) 452018. Submission of Financials for the Half year ended 30.09.2024 (As Per BSE Announcement dated on 11.11.2024)
02-Aug-2024	12-Aug-2024	Quarterly Results	SYNCOM FORMULATIONS (INDIA) LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2024 inter alia to consider and approve Pursuant to Regulation 29(1) (a) of SEBI (LODR) Regulations 2015 read with SEBI (PIT) Regulations 2015 as amended from time to time we are pleased to inform that 2/2024-25 Meeting of the Board of Directors of the Company is scheduled to be held on Monday the 12th day of August 2024at 4:00 P.M. at the Corporate Office situated at 207 Saket Nagar Near Saket Club Indore (M.P.) 452018 Submission of Unaudited Standalone and Consolidated financial Results for the quarter ended 30.06.2024 (As Per BSE Announcement Dated on: 12/08/2024)
09-May-2024	17-May-2024	Accounts	SYNCOM FORMULATIONS (INDIA) LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/05/2024 inter alia to consider and approve Pursuant to Regulation 29(1) (a) of SEBI (LODR) Regulations 2015 read with SEBI (PIT) Regulations 2015 as amended from time to time we are pleased to inform that 1/2024-25 Meeting of the Board of Directors of the Company is scheduled to be held on Friday the 17th day of May 2024 at 4:00 P.M. at the Corporate Office situated at 207 Saket Nagar Near Saket Club Indore (M.P.) 452018 to consider and approve the following businesses along with other routine businesses: a) To consider and approve Standalone and Consolidated Audited Financial Results of the Company for the Quarter and year ended 31st March 2024; b) To take on record the Standalone and Consolidated Audit Report by Auditors for the Audited Financial Results of the Company for the Quarter and year ended 31st March 2024. c) To consider and approve other matter incidental thereto. Publication of Financial Results for year ended 31.03.2024 (As Per BSE Announcement Dated on 18.05.2024)
06-Feb-2024	14-Feb-2024	Quarterly Results	SYNCOM FORMULATIONS (INDIA) LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2024 inter alia to consider and approve Pursuant to Regulation 29(1) (a) of SEBI (LODR) Regulations 2015 read with SEBI (PIT) Regulations 2015 as amended from time to time we are pleased to inform that 5/2023-24 Meeting of the Board of Directors of the Company is scheduled to be held on Wednesday the 14th day of February 2024 at 11:00 A.M. at the Corporate Office situated at 207 Saket Nagar Near Saket Club Indore (M.P.) 452018 submission of unaudited standalone and consolidated financials for the quarter ended 31.12.2023 (As per BSE Announcement Dated on 14/02/2024)
27-Oct-2023	08-Nov-2023	Quarterly Results	SYNCOM FORMULATIONS (INDIA) LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/11/2023 inter alia to consider and approve With Reference to Regulation 29(1)(a) of SEBI (LODR) Regulations 2015 read with SEBI (PIT) Regulations 2015 we are pleased to inform that 4/2023-24 Meeting of the Board of directors of the Company is scheduled to be held on Wednesday 8th November 2023 at 11:00 A.M. at the Corporate office of the Company situated at 207 Saket Nagar near Saket Club Indore (M.P.) 452018 to consider and approve the following businesses :1.Approval of the Standalone and Consolidated Un-audited Financial Results for the Quarter and half year ended on 30th September 2023.2.To take on record the Limited Review Report by the Statutory Auditors for Un-audited Financial Results for the Quarter half year ended on 30th September 2023.3.Approval of the Standalone and Consolidated Un-audited Statement of Assets and Liabilities for the half-year ended 30th September 2023.4.Approval of the Standalone and Consolidated Un-audited Statement of Cash Flow for the half-year ended 30th September 2023. Regulation 33(3)(d) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 - Submission of Standalone & Consolidated Un-Audited Financial Results along with Limited Review Report thereon for the Quarter and Half year ended on 30th September, 2023. (As Per BSE Announcement dated on 08.11.2023)
03-Aug-2023	14-Aug-2023	Quarterly Results	SYNCOM FORMULATIONS (INDIA) LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2023 inter alia to consider and approve we are pleased to inform that 3/2023-24 Meeting of the Board of Directors of the Company is scheduled to be held on Monday the 14th day of August 2023 at 11:00 A.M. at the Corporate Office situated at 207 Saket Nagar Near Saket Club Indore (M.P.) 452018to consider and approve the following businesses along with other routine businesses: a) To consider and approve Standalone and consolidated Un-audited Financial Results of the Company for the Quarter ended 30th June 2023; b) To take on record the Standalone and consolidated Limited Review Report by Auditors for the Financial Results of the Company for the Quarter ended 30th June 2023; c) To consider and approve other matter incidental thereto. This has in reference to our letter No. SYNCOM/SE/2023-24 dated 3rd August,2023 for notice under Regulation 29(1)(a) of SEBI (LODR) Regulations,2015 read with Regulation 30 of SEBI (LODR) Regulations,2015 and Schedule III of the said Regulations, by which it was informed that meeting No. 3/2023-24 of the Board of directors of the Company is to be held on Monday,14thAugust, 2023 at11:00 A.M (As Per BSE Announcement Dated on 14.08.2023) Pursuant to Reg 30 we enclose the newspaper advertisement published on 15.08.2023 in Free Press journal English Edition and Marathi Vernacular Newspaper. (As Per BSE Announcement Dated on 15/08/2023)
20-May-2023	29-May-2023	Accounts	SYNCOM FORMULATIONS (INDIA) LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2023 inter alia to consider and approve the following businesses along with other routine businesses: a) To consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the Quarter/Year ended 31st March 2023 . b) To take on record the Audit Report of the Statutory Auditors for the Standalone and Consolidated Audited Financial Results of the Company for the Quarter/Year ended 31st March 2023. c) To consider and approve the Standalone and Consolidated Audited Financial Statements including the Balance Sheet as at 31st March 2023 and the Statement of Profit and Loss and Cash Flow Statement Change in Equity and notes thereon for the year ended 31st March 2023. Pursuant to Regulation 33(3)(d) of SEBI (LODR) Regulations, 2015, we are pleased to submit the Standalone & Consolidated Audited Financial Results along with Auditors' Report thereon by Statutory Auditors, Statement of Assets and Liabilities and Cash Flow for the quarter/year ended on 31st March, 2023, in PDF Format, which were also approved by the Audit Committee and Board of Directors at their meeting held on Monday, 29th May, 2023. Since, the Auditor's Report is self-explanatory and has no modification/qualification; it needs no further comments by the Company. We are also in process to file the aforesaid financial results in XBRL format within the stipulated time and the same shall also be hosted on the website of the company. The Financial Results will also be published in widely circulated English and Hindi (Vernacular) newspaper in the prescribed format within the stipulated time period. The Board Meeting was commenced at 4:00 P.M. and concluded at 8:00 P.M. (As Per BSE Announcement Dated on 29.05.2023) Pursuant to Regulation 30 read with Schedule III Part A(A) and in compliance of Regulation 47(1)(b) of SEBI (LODR) Regulations, 2015 regarding extract of Audited Standalone and Consolidated Quarter/Year ended Financial Results for the Quarter/Year ended 31stMarch, 2023 was also approved by the Audit Committee and Board of Directors at their meeting held on Monday, 29thMay, 2023. (As Per BSE Announcement dated on 31.05.2023)
02-May-2023	02-May-2023	Change in Other Executives	Company has appointed CS Vaishali Agrawal (ACS: 51833) as a Company Secretary and Key Managerial Person and further as a Compliance Officer of the Company at the Board meeting held on 2nd May, 2023, w.e.f. 3rd May, 2023 We would like to inform that CS Prachi Jain, Company Secretary and Compliance Officer of the Company has placed her resignation which was accepted in the Board Meeting held on 2nd May, 2023. Further the Company has appointed CS Vaishali Agrawal (ACS: 51833) as a Company Secretary and Key Managerial Person and further as a Compliance Officer of the Company at the Board meeting held on 2nd May, 2023,w.e.f. 3rd May, 2023
02-Feb-2023	13-Feb-2023	Quarterly Results	SYNCOM FORMULATIONS (INDIA) LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2023 inter alia to consider and approve 1. the Standalone and Consolidated Un-audited Quarter and Nine Months ended Financial Results of the Company for the Quarter and Nine Months ended on 31st December 2022. 2. Limited Review Report by the Statutory Auditors for Financial Results of the company for the Quarter and Nine Months ended on 31st December 2022. 3. And other Routine Business. This is in continuation of our letter no. SYNCOM/SE/2022-23 dated 2nd February, 2023 regarding intimation of Board meeting for consideration and approval of Standalone and Consolidated Un-Audited Financial Results for the Quarter and Nine Months ended 31st December, 2022. Pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015, we are pleased to the following: 1. Standalone and Consolidated Unaudited Financial Results of the Company for the Quarter and Nine Months ended on 31st December, 2022; 2. Standalone and Consolidated Limited Review Report by the Statutory Auditors of the company for the Quarter and Nine Months ended on 31st December, 2022. which was considered and approved by the Board at their 7/2022-23 Meeting held on Monday, the 13th February, 2023. The meeting of the Board of Directors commenced at 4:00 P.M. and concluded at 8:00 P.M. (As Per BSE Announcement dated on 13.02.2023) Pursuant to Regulation 30 read with Schedule III Part A(A)and in compliance of Regulation 47(1)(b) of SEBI (LODR) Regulations, 2015 regarding extract of Standalone and Consolidated Un-Audited Quarter and Nine Month ended Financial Results for the Quarter and Nine Month ended 31st December, 2022 was also approved by the Audit Committee and Board of Directors at their meeting held on Monday, 13th February, 2023. We herewith enclose the newspaper advertisement published on 15th February,2023 in Free Press Journal English edition and Marathi (vernacular) Newspaper. (As Per BSE Announcement dated on 15.02.2023)
02-Nov-2022	14-Nov-2022	Quarterly Results	SYNCOM FORMULATIONS (INDIA) LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2022 inter alia to consider and approve 1. the Standalone and Consolidated Un-audited Half Yearly/Quarterly Financial Results of the Company for the Half Year/Quarter ended on 30th September 2022; 2. the Limited Review Report by the Statutory Auditors for Financial Results of the company for the Half Year/Quarter ended on 30th September 2022; 3. the Standalone and Consolidated Un-Audited Statement of Assets and Liabilities for the Half year/Quarter ended on 30th September 2022; and 4. the Standalone and Consolidated Un-Audited Statement of Cash Flow for the Half year/Quarter ended on 30th September 2022. This is in continuation of our letter dated 2nd November, 2022 regarding intimation of Board meeting for consideration and approval of Standalone and Consolidated Un-Audited Financial Results for the Half Year/ Quarter ended 30th September, 2022.Pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015, we are pleased to the following: 1. Standalone and Consolidated Unaudited Half Yearly/Quarterly Financial Results of the Company for the Half Year/Quarter ended on 30th September, 2022; 2. Standalone and Consolidated Limited Review Report by the Statutory Auditors of the company for the Half Year/Quarter ended on 30th September, 2022; 3. Standalone and Consolidated Un-Audited Statement of Assets and Liabilities for the Half year ended on 30th September, 2022; and 4. Standalone and Consolidated Un-Audited Statement of Cash Flow for the Half year ended on 30th September, 2022. which was considered and approved by the Board at their Meeting held on Monday, the 14th November, 2022. (As Per BSE Announcement Dated on 14/11/2022) Pursuant to Regulation 30 read with Schedule III Part A(A) and in compliance of Regulation 47(1)(b) of SEBI (LODR) Regulations, 2015 regarding extract of Standalone and Consolidated Un-Audited Quarter and Half Year ended Financial Results for the Quarter and Half Year ended 30th September, 2022 was also approved by the Audit Committee and Board of Directors at their meeting held on Monday, 14th November, 2022. We herewith enclose the newspaper advertisement published on 16th November, 2022 in Free Press Journal English edition and Marathi (vernacular) Newspaper. This is with reference to the above captioned subject, regarding Additional details required by the email dated 16th Nov., 2022 at 4.32 P.M.as required under SEBI Circular dated September 09, 2015, for Corporate Announcement filed under Regulation 30 of SEBI (LODR) Regulations, 2015 with respect to the disclosure of Unaudited Quarterly Financial Results for the quarter ended 30th Sept., 2022 observed by the BSE that 'Board Meeting Concluded Time not Given'. It may please be considered that the said Board Meeting was concluded at 9.00 P.M. on 14th Nov., 2022 and the time of meeting conclusion was also disclosed while filing of results in the XBRL at the portal of BSE. This may be considered as compliance as required under Regulation 30 of the SEBI (LODR) Regulation as required under in the Para No. 4 of the Annexure of the Circular No. CIR/CFD/CMD/4/2015 dated 09.09.2015. As per the aforesaid email we are pleased to submit a fresh corporate announcement for the aforesaid purposes. (As Per BSE Announcement Dated on 16/11/2022)
01-Aug-2022	13-Aug-2022	Quarterly Results	SYNCOM FORMULATIONS (INDIA) LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2022 inter alia to consider and approve a) the Un-audited Financial Results of the Company for the Quarter ended 30th June 2022; b) the LRR by Auditors for the Financial Results of the Company for the Quarter ended 30.06.22.; c) the Boards Report Corporate Governance Report and Notice of the 34th AGM; d) the Book closure for the purpose of 34th AGM; e) the cut-off date for eligibility to participate in the Remote E-voting and E- voting at 34th AGM; f) To appoint Scrutinizer for the process of remote E-voting as well as E-voting at AGM; g) Re-appointment of Smt. Rinki Ankit Bankda (DIN: 06946754) as the Whole-time Director of the Company; h) To consider and recommend the Final dividend if any on equity shares of the Company for the Financial Year ended 31st March 2022 subject to approval of members at the ensuing AGM; i) To consider the matter related to appointment/re-appointment of Statutory Auditor upon conclusion of the term of 5 years in the ensuing AGM; j) To consider and approve other matter incidental thereto. Pursuant to Regulation 33(3)(d) of SEBI (LODR) Regulations, 2015, we are pleased to submit the Un-Audited Financial Results along with Limited Review Report thereon for the quarter ended 30th June, 2022, in PDF Format, which were also approved by the Audit Committee and Board of Directors at their meeting held on Saturday, 13th August, 2022. Outcome of the 5/2022-23 Meeting of the Board of Directors of the Company held on Saturday, 13th August, 2022 at 207, Saket Nagar, Near Saket Club, Indore (M.P.) 452018 at 4:00 P.M. as per Regulation 30 read with Schedule III(A)(IV) of the SEBI(LODR) Regulations, 2015. (As Per BSE Announcement Dated on 13/08/2022) Corporate Announcement for recommendation of Dividend @ Rs. 0.03 (3%) per share on the 94,00,00,000 Equity Shares of Rs.1/- each of the Company for the Financial year 2021-22. (As Per BSE Announcement Dated on 16.08.2022)
28-Jun-2022	28-Jun-2022	Change in Directors	Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, we submit the outcome of the meeting of the Board of Directors of the Company held on Tuesday on 28th June, 2022 at 4:00 P.M. and concluded at 5:00 P.M. You are requested to please take on record the above said document for your reference & further needful.
21-May-2022	28-May-2022	Conversion	SYNCOM FORMULATIONS (INDIA) LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2022 inter alia to consider and approve (a) the conversion of warrants into the equity shares of the Company to the Promoter and Promoter Group subject to the depositing the balance outstanding amount for conversion of warrants into the equity shares of the Company. (b)any other matter incidental thereto. This has in reference to our letter No. SYNCOM/SE/2022-23 dated 23rd May, 2022 for notice under Regulation 29(1)(a) of SEBI (LODR) Regulations, 2015 read with Regulation 30 of SEBI (LODR) Regulations, 2015 and Schedule III of the said Regulations, by which it was informed that a meeting No. 3/2022-23 of the Board of Directors of the Company is to be held on Saturday, 28th May, 2022 at 1:00 P.M. You are requested to please take on record our above said information for your reference and record and disseminate on the portal of the BSE for information to the investors and members of the Company. This is to inform you that the Directors of the Company in their Board Meeting held on 28th May, 2022 has approved the conversion of 7,75,47,000 (Seven Crores Seventy Five Lakhs Forty Seven Thousand) convertible warrants into equity shares pursuant to exercise of option attached to said convertible warrants by the warrant holders and accordingly allot 7,75,47,000 equity shares of face value Rs.1/- each at a premium of Rs.1.53/- per share. The above is for your kind information and record. (As per BSE Announcement Dated on 28.05.2022)
10-May-2022	18-May-2022	Accounts	SYNCOM FORMULATIONS (INDIA) LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/05/2022 inter alia to consider and approve (a) the Audited Financial Results of the Company for the Quarter/Year ended 31st March 2022. b)the Audit Report of the Statutory Auditors for the Audited Financial Results of the Company for the Quarter/Year ended 31st March 2022. c) the Audited Financial Statements including the Balance Sheet as at 31st March 2022 and the Statement of Profit and Loss and Cash Flow Statement Change in Equity and notes thereon for the year ended 31st March 2022. You are requested to please take on record our above said information for your reference and disseminate on the website of the BSE. Submission of the Audited Financial Results along with Auditors' Report thereon for the Quarter/Year ended 31st March, 2022 as per Regulation 33(3)(d) of SEBI (LODR) Regulations, 2015. (As Per BSE Announcement dated on 18.05.2022)

1 2

LOGIN HERE

Syncom Formulations (India) Ltd

Board Meeting